



COVID-19 VACCINATION IN MANITOBA

TECHNICAL BRIEFING

March 3, 2021

OPERATIONAL UPDATES



VACCINE DELIVERY MODEL UPDATES



SUPERSITES

In larger centres, supersites allow for rapid and large-scale vaccination for increased speed and efficiency.

3

Winnipeg

6,945

DOSES ADMINISTERED
IN LAST WEEK

39,649

TOTAL DOSES
ADMINISTERED

777

AVG. DAILY DOSES

55

EST. DAILY STAFF (FTE)

Brandon

1,473

DOSES ADMINISTERED
IN LAST WEEK

5,279

TOTAL DOSES
ADMINISTERED

165

AVG. DAILY DOSES

27

EST. DAILY STAFF (FTE)

Thompson

350

DOSES ADMINISTERED
IN LAST WEEK

350

TOTAL DOSES
ADMINISTERED

116

AVG. DAILY DOSES

14

EST. DAILY STAFF (FTE)



FOCUSED IMMUNIZATION TEAMS (FITs)

FITs visit facilities to deliver vaccines where people live.


- FITs will visit 120 congregate living facilities this week and administer about 4,800 residents
- More than 7,800 second-doses in personal care home immunization campaign
- All regional health authorities have scheduled prioritized congregate living sites this week.

WORKFORCE RECRUITMENT



DAILY OPERATIONAL SCHEDULE

Overall, staffing is down due to lack of vaccine




CURRENT WORKFORCE



- 1,647 immunizers
- 20 clinic managers
- 27 clinical leads
- 426 navigators
- 104 observers

COVID-19 DOSE DELIVERY SCHEDULE




As of March 2, 2021

SUPERSITE INVENTORY MANAGEMENT

Projected for the next 30 days



Closing Stock Balance - Supersites




Projections as of March 2. Each rise in doses represents a scheduled delivery.

DOSE ADMINISTRATION PROJECTION



- Based on current supply projections, we estimate an average of 2,277 injections per day in March, subject to current vaccine supply forecasts.



Projected as of March 2

LOW-RANGE SCENARIO



Based on Pfizer and Moderna vaccines.

Allocation details on AstraZeneca have not been provided to Manitoba yet.

Cohort	Population Cohort	Start	Finish	Duration	2021											
					Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	Healthcare Workers	16-Dec-2020	30-Jul-2021	32.6w	[Orange bar spanning Dec 2020 to Jul 2021]											
2	Personal Care Home Residents	11-Jan-2021	12-Mar-2021	9w	[Orange bar spanning Jan to Mar 2021]											
3	Other congregate living settings	19-Feb-2021	30-Apr-2021	10.2w	[Orange bar spanning Feb to Apr 2021]											
4	FN general population 60+	15-Mar-2021	14-May-2021	9w	[Orange bar spanning Mar to May 2021]											
5	General population 80+	15-Mar-2021	14-May-2021	9w	[Orange bar spanning Mar to May 2021]											
6	FN general population 50-59	01-Apr-2021	28-May-2021	8.4w	[Orange bar spanning Apr to May 2021]											
7	General population 70-79	01-Apr-2021	28-May-2021	8.4w	[Orange bar spanning Apr to May 2021]											
8	FN general population 40-49	03-May-2021	29-Jun-2021	8.4w	[Orange bar spanning May to Jun 2021]											
9	General population 60-69	03-May-2021	29-Jun-2021	8.4w	[Orange bar spanning May to Jun 2021]											
10	FN general population 30-39	01-Jun-2021	29-Jul-2021	8.6w	[Orange bar spanning Jun to Jul 2021]											
11	General population 50-59	01-Jun-2021	29-Jul-2021	8.6w	[Orange bar spanning Jun to Jul 2021]											
12	FN general population 18-29	02-Aug-2021	30-Sep-2021	8.8w	[Orange bar spanning Aug to Sep 2021]											
13	General population 40-49	02-Aug-2021	30-Sep-2021	8.8w	[Orange bar spanning Aug to Sep 2021]											
14	General population 30-39	03-Sep-2021	29-Oct-2021	8.2w	[Orange bar spanning Sep to Oct 2021]											
15	General population 18-29	01-Oct-2021	30-Nov-2021	8.6w	[Orange bar spanning Oct to Nov 2021]											

Projected as of March 2

HIGH-RANGE SCENARIO



Based on Pfizer, Moderna, AstraZeneca and other vaccines that have not yet been approved

Cohort	Population Cohort	Start	Finish	Duration	2021													
					Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		
1	Healthcare Workers	16-Dec-2020	28-May-2021	23.6w	█													
2	Personal Care Home Residents	11-Jan-2021	12-Mar-2021	9w		█												
3	Other congregate living settings	19-Feb-2021	28-Apr-2021	9.8w			█											
4	FN general population 60+	15-Mar-2021	14-May-2021	9w			█											
5	General population 80+	15-Mar-2021	14-May-2021	9w			█											
6	FN general population 50-59	01-Apr-2021	31-May-2021	8.6w				█										
7	General population 70-79	01-Apr-2021	31-May-2021	8.6w				█										
8	FN general population 40-49	15-Apr-2021	31-May-2021	6.6w				█										
9	General population 60-69	15-Apr-2021	31-May-2021	6.6w				█										
10	FN general population 30-39	03-May-2021	30-Jun-2021	8.6w					█									
11	General population 50-59	03-May-2021	30-Jun-2021	8.6w					█									
12	FN general population 18-29	01-Jun-2021	30-Jul-2021	8.8w						█								
13	General population 40-49	01-Jun-2021	30-Jul-2021	8.8w						█								
14	General population 30-39	01-Jul-2021	31-Aug-2021	8.8w							█							
15	General population 18-29	15-Jul-2021	31-Aug-2021	6.8w								█						

Projected as of March 2

DELIVERING 1.5 MILLION DOSES



SECOND QUARTER EXPANSION

Building from Manitoba's small, deliberate and safe starting point to deliver the largest immunization campaign in provincial history



- Manitoba continues to report **Daily Maximum Capacity**
- This shows how many doses could be delivered on any given day in Manitoba if we had adequate supply.
- This will be updated as new facilities and staff are added to increase capacity.

Site / Approach	Daily Maximum Capacity
Supersites (RBC, Backup Site, Keystone, Thompson, Vaxport)	6,499
Distributed Model	5,000
Focused Immunization Teams	500
Pop-up Clinics	500
Current Daily Maximum Capacity	12,499
TARGET CAPACITY Q2	20,000

CONTINUED PROGRESS



Protecting Manitobans, Building Capacity

- First general population immunizations on March 1
- Regular expansions of eligibility criteria
- Vaxport pilot project underway
- Selkirk supersite opens March 8, appointments being booked now
- Morden supersite to open mid-March
- PCH 2nd dose campaign complete
- Congregate living facility 1st dose campaign underway



VACCINE TECHNOLOGY

COVID-19 Vaccines

Multiple vaccines in various stages

Each approved vaccine, particularly those using different technologies, will have different indications for use



Approved vaccines:

- Pfizer-BioNTech approved Dec. 9, 2020
- Moderna approved Dec. 23, 2020
- AstraZeneca/Covishield approved Feb. 26, 2021

More vaccines expected to be approved Q2+:

- Johnson & Johnson*
- Novavax
- Sanofi and GSK
- Medicago

**FDA approved Johnson & Johnson one-shot vaccine, Janssen, on Feb. 27, 2021.*

Vaccine Supply

Supply to Canada is Expected to Increase

- Supply is expected to increase exponentially in Q2 as more vaccines are approved and currently-approved vaccines ramp up production
- Over 70,000 doses of mRNA vaccine (Pfizer and Moderna) administered in Manitoba to date
- Supply of AstraZeneca expected by mid-March



COVID-19 Vaccine Agreements in Canada



Supplier / Vaccine	Technology Platform	Doses	Status
AstraZeneca	Viral vector	20 million	Approved Feb. 2021
Moderna	mRNA	44 million	Approved Dec. 2020
Pfizer-BioNTech	mRNA	Up to 76 million	Approved Dec. 2020
Johnson & Johnson	Viral vector	Up to 38 million	Under review; submitted to Health Canada Nov. 11, 2020
Medicago	Plant-based	Up to 76 million	Phase III; anticipated to seek licensure Q3, 2021.
Novavax	Subunit protein	Up to 76 million	Under review; submitted to Health Canada Jan. 29, 2021
Sanofi and GlaxoSmithKline	Subunit protein	Up to 72 million	Phase II; anticipated to seek licensure Q4, 2021.

Does not include provincially-procured vaccines

Vaccinology



- The three vaccines currently authorized for use in Canada (Pfizer –Biontech mRNA, Moderna mRNA, and Astra Zeneca DNA) protect us from COVID-19 infection using a different approach than other, more familiar vaccines.
- For example: The measles vaccine fuses a weakened live virus that causes our immune system to produce protective antibodies and immune system cells. Flu vaccines use inactivated virus to do the same.
- The COVID-19 vaccines use RNA or DNA that provide the instructions for our immune system to manufacture the protein that causes our immune system to produce protective antibodies and immune cells.

mRNA Vaccines

Pfizer-BioNTech and Moderna



- **Storage:** ultra-frozen (70°C) for Pfizer and frozen (-20°C) for Moderna
- **Authorized ages:** 16+ for Pfizer and 18+ for Moderna
- **Schedule:** 2 doses, 3-4 weeks apart.

mRNA Vaccine Effectiveness

Pfizer-BioNTech and Moderna



- Both mRNA vaccines were shown to be safe and effective in preventing lab confirmed COVID-19 infection after two doses (with effectiveness around 94-95%).
- However, significant protection started about 12-14 days after the first dose and may be above 90% in the clinical trials.
- Emerging 'real world' evidence from the UK, Scotland and Israel suggests that one dose of mRNA vaccine is 70-80% effective in preventing lab confirmed COVID-19 infection and also significantly reduced hospitalization and death.
- Effectiveness against variants of concern is evolving.

Viral Vector (DNA) Vaccines

AstraZeneca

- **Storage:** Routine at 2°C to 8°C
- **Authorized age:** 18+
- **Schedule:** 2 doses, 4-12 weeks apart (12 weeks preferred)



Viral Vector (DNA) Vaccine Effectiveness

AstraZeneca



- Although the initial clinical trial results showed the AstraZeneca vaccine to be moderately effective (around 60%), a subsequent analysis of the data shows that longer intervals between dose 1 and dose 2 (12 weeks) resulted in effectiveness >80%.
- Real world data from the United Kingdom in those 70+ are showing single dose effectiveness >70% and a significant reduction in hospitalization and death.
- Data on effectiveness against variants of concern is evolving.

Ongoing Evaluation

All vaccines continue to be monitored for safety and effectiveness after they are authorized for use



- Ongoing clinical trials
- Ongoing real-world effectiveness studies
- Federal adverse events following immunization (AEFI) system
- Provincial table reviews any reports of AEFI and collaborates with national tables
- Vaccine safety is monitored more closely than any other medical intervention

Which Vaccine Should I Get?



- If you are eligible to be immunized, the answer is simple: The first vaccine available to you.
- Locations where you can get vaccines will expand, and there will be more types of vaccines available over time.
- But this is key: All vaccines approved for use are effective in preventing you from getting COVID-19, and in reducing the seriousness of your symptoms
- Being immunized with one type of vaccine now will not prevent you from getting another type of COVID-19 vaccine in the future, when supplies are greater
- Get the facts on COVID-19 vaccine from reliable sources
- Vaccines are safe, effective and are a life-saving intervention



COVID-19 VACCINATION IN MANITOBA QUESTIONS?

Media are invited to provide feedback on future tech briefings or
specific areas of interest to lenore.kowalchuk@gov.mb.ca